menu ☰
menu ˟

Investigational JAK1 inhibitor enters phase 3 for rheumatoid arthritis treatment

12 Jan 2016
AbbVie Inc. announced its oral, selective JAK1 inhibitor, ABT-494, has entered a phase 3 for with patients with rheumatoid arthritis as part of a program of five trials, according to a company press release.The study reportedly follows positive resul...

Click here to view the full article which appeared in Rheumatology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.